Cargando…

Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit

BACKGROUND: Perioperative C‐reactive protein (CRP) levels have effects on the prognosis of cancer patients. We intended to determine the prognostic value of combining the two for gastric cancer (GC). METHODS: Data were extracted from a clinical trial. By calculating the area under the curve (AUC) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Jun, Xu, Bin‐Bin, Xue, Zhen, Xie, Jian‐Wei, Zheng, Chao‐Hui, Huang, Chang‐Ming, Li, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826470/
https://www.ncbi.nlm.nih.gov/pubmed/33270989
http://dx.doi.org/10.1002/cam4.3514
_version_ 1783640527894216704
author Lu, Jun
Xu, Bin‐Bin
Xue, Zhen
Xie, Jian‐Wei
Zheng, Chao‐Hui
Huang, Chang‐Ming
Li, Ping
author_facet Lu, Jun
Xu, Bin‐Bin
Xue, Zhen
Xie, Jian‐Wei
Zheng, Chao‐Hui
Huang, Chang‐Ming
Li, Ping
author_sort Lu, Jun
collection PubMed
description BACKGROUND: Perioperative C‐reactive protein (CRP) levels have effects on the prognosis of cancer patients. We intended to determine the prognostic value of combining the two for gastric cancer (GC). METHODS: Data were extracted from a clinical trial. By calculating the area under the curve (AUC) and the C‐index, the predictive value of CRPs among different time points, including preoperative (pre‐CRP), postoperative days 1, 3, and 5 (post‐CRPs), and postoperative maximum CRP (post‐CRP(max)), was derived. Multivariate analysis was performed to further explore the independent variates for recurrence‐free survival (RFS). RESULTS: Finally, 401 patients were available in the present study. For RFS, higher AUC (0.692) and concordance index (0.678) of pre‐CRP were observed when compared with those of post‐CRPs. Further, among post‐CRPs, post‐CRP(max) had the highest predictive values (AUC: 0.591; concordance index: 0.585) among the other post‐CRPs. The threshold values in predicting RFS for pre‐CRP and post‐CRP(max) were 3.1 mg/L and 77.1 mg/L. Multivariate analysis showed both pre‐CRP≥3.1 mg/L (high‐pre‐CRP) and post‐CRP(max)≥77.1 mg/L (high‐post‐CRP(max)) were risk factors for RFS. Postoperative chemotherapy benefit was further analyzed for patients with stage II/III GC and indicated that patients with pre‐CRP<3.1 mg/L had better prognosis without benefit from postoperative adjuvant chemotherapy (ACT), p = 0.557. In high‐pre‐CRP patients, only patients with post‐CRP(max)≥77.1 mg/L but not post‐CRP(max)<77.1 mg/L benefited from postoperative ACT (RFS: 33.2% vs 49.9% for non‐chemotherapy group and chemotherapy group, respectively, p = 0.037). Analyses for overall survival obtained the similar outcomes. CONCLUSIONS: Both high‐pre‐CRP and high‐post‐CRP(max) are associated with worse prognosis in GC. ACT seems to only improve the prognosis for stage II/III GC with pre‐CRP≥3.1 mg/L and post‐CRP(max)≥77.1 mg/L after radical gastrectomy. Further studies are needed to confirm these findings and explore the potential mechanism.
format Online
Article
Text
id pubmed-7826470
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78264702021-02-01 Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit Lu, Jun Xu, Bin‐Bin Xue, Zhen Xie, Jian‐Wei Zheng, Chao‐Hui Huang, Chang‐Ming Li, Ping Cancer Med Clinical Cancer Research BACKGROUND: Perioperative C‐reactive protein (CRP) levels have effects on the prognosis of cancer patients. We intended to determine the prognostic value of combining the two for gastric cancer (GC). METHODS: Data were extracted from a clinical trial. By calculating the area under the curve (AUC) and the C‐index, the predictive value of CRPs among different time points, including preoperative (pre‐CRP), postoperative days 1, 3, and 5 (post‐CRPs), and postoperative maximum CRP (post‐CRP(max)), was derived. Multivariate analysis was performed to further explore the independent variates for recurrence‐free survival (RFS). RESULTS: Finally, 401 patients were available in the present study. For RFS, higher AUC (0.692) and concordance index (0.678) of pre‐CRP were observed when compared with those of post‐CRPs. Further, among post‐CRPs, post‐CRP(max) had the highest predictive values (AUC: 0.591; concordance index: 0.585) among the other post‐CRPs. The threshold values in predicting RFS for pre‐CRP and post‐CRP(max) were 3.1 mg/L and 77.1 mg/L. Multivariate analysis showed both pre‐CRP≥3.1 mg/L (high‐pre‐CRP) and post‐CRP(max)≥77.1 mg/L (high‐post‐CRP(max)) were risk factors for RFS. Postoperative chemotherapy benefit was further analyzed for patients with stage II/III GC and indicated that patients with pre‐CRP<3.1 mg/L had better prognosis without benefit from postoperative adjuvant chemotherapy (ACT), p = 0.557. In high‐pre‐CRP patients, only patients with post‐CRP(max)≥77.1 mg/L but not post‐CRP(max)<77.1 mg/L benefited from postoperative ACT (RFS: 33.2% vs 49.9% for non‐chemotherapy group and chemotherapy group, respectively, p = 0.037). Analyses for overall survival obtained the similar outcomes. CONCLUSIONS: Both high‐pre‐CRP and high‐post‐CRP(max) are associated with worse prognosis in GC. ACT seems to only improve the prognosis for stage II/III GC with pre‐CRP≥3.1 mg/L and post‐CRP(max)≥77.1 mg/L after radical gastrectomy. Further studies are needed to confirm these findings and explore the potential mechanism. John Wiley and Sons Inc. 2020-12-03 /pmc/articles/PMC7826470/ /pubmed/33270989 http://dx.doi.org/10.1002/cam4.3514 Text en © 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Lu, Jun
Xu, Bin‐Bin
Xue, Zhen
Xie, Jian‐Wei
Zheng, Chao‐Hui
Huang, Chang‐Ming
Li, Ping
Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
title Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
title_full Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
title_fullStr Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
title_full_unstemmed Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
title_short Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
title_sort perioperative crp: a novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826470/
https://www.ncbi.nlm.nih.gov/pubmed/33270989
http://dx.doi.org/10.1002/cam4.3514
work_keys_str_mv AT lujun perioperativecrpanovelinflammationbasedclassificationingastriccancerforrecurrenceandchemotherapybenefit
AT xubinbin perioperativecrpanovelinflammationbasedclassificationingastriccancerforrecurrenceandchemotherapybenefit
AT xuezhen perioperativecrpanovelinflammationbasedclassificationingastriccancerforrecurrenceandchemotherapybenefit
AT xiejianwei perioperativecrpanovelinflammationbasedclassificationingastriccancerforrecurrenceandchemotherapybenefit
AT zhengchaohui perioperativecrpanovelinflammationbasedclassificationingastriccancerforrecurrenceandchemotherapybenefit
AT huangchangming perioperativecrpanovelinflammationbasedclassificationingastriccancerforrecurrenceandchemotherapybenefit
AT liping perioperativecrpanovelinflammationbasedclassificationingastriccancerforrecurrenceandchemotherapybenefit